Patent · US Active

Molecular design of recombinant protein drug

US10869910B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

TSINGHUA UNIVERSITY · CN
BEIJING PROTGEN LTD. · CN

Inventors

Yongzhang Luo · Beijing, CN
Peng Liu · Beijing, CN
Xinan LU · Beijing, CN

Key dates

Filing date	Feb 14, 2016
Grant date	Dec 22, 2020
Priority date	—
Expiry date	Sep 11, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/78
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.